Read twice and referred to the Committee on Commerce, Science, and Transportation.
This bill (Aviation Medication Transparency Act of 2025) requires the FAA Administrator to publish and maintain, on a publicly available FAA website, a list of medications the FAA has determined may be safely prescribed to applicants for airmen and air traffic control specialist medical certification and medications approved for certification. The list must be drafted in consultation with the Aeromedical Innovation and Modernization Working Group, accredited aviation higher-education institutions, certified bargaining representatives for air traffic controllers and pilots, and other stakeholders the Working Group identifies.
Transparency and worker safety vs. concerns about adding federal bureaucracy and cost.
Relative to its intended legislative type, this bill clearly defines a limited administrative task (publish and maintain a medication list for FAA medical certification), prescribes required content and stakeholder consultation, and sets reasonable deadlines.
This bill (Aviation Medication Transparency Act of 2025) requires the FAA Administrator to publish and maintain, on a publicly available FAA website, a list of medications the FAA has determined may be safely prescribed to applicants for airmen and air traffic control specialist medical certification and medications approved for certification.
The list must be drafted in consultation with the Aeromedical Innovation and Modernization Working Group, accredited aviation higher-education institutions, certified bargaining representatives for air traffic controllers and pilots, and other stakeholders the Working Group identifies.
The list must cover prescription and over-the-counter medications, be user-friendly, be provided to individuals when they first seek medical certification, indicate any minimum or average stabilization periods if applicable, include a “Do Not Issue” list, provide contact information for providers to reach the FAA with questions, and include other explanatory material the Administrator deems appropriate.
On content alone, this is a low-controversy, administratively focused bill that improves transparency and involves stakeholder input. It has limited fiscal impact and fits within existing FAA responsibilities, characteristics that historically increase chances of enactment. Passage still depends on procedural scheduling, committee priorities, and whether opponents raise specific technical or resource concerns during markup or amendment.
Relative to its intended legislative type, this bill clearly defines a limited administrative task (publish and maintain a medication list for FAA medical certification), prescribes required content and stakeholder consultation, and sets reasonable deadlines. It is moderately well-constructed for an operational directive but omits fiscal direction, detailed criteria and methodology for list content, and formal accountability or dispute-resolution mechanisms.
Transparency and worker safety vs. concerns about adding federal bureaucracy and cost.
These are examples from the analysis, not a ranked list of the most-affected groups.
Transparency and worker safety vs. concerns about adding federal bureaucracy and cost.
A mainstream liberal would likely view the bill positively as a transparency and safety measure that helps workers and trainees understand which medications affect medical certification.
They would appreciate mandated consultation with worker representatives, educational institutions, and the aeromedical working group.
They may still want assurances that the list will not be used to stigmatize treatment or create barriers to care, and may press for clear appeals or exemption processes for legitimate medical needs.
A centrist/moderate would likely see the bill as a practical, incremental transparency measure that mostly formalizes information the FAA already uses in certification.
They would favor the stakeholder consultation requirement and annual updates, but would want to ensure the list is evidence-based and does not impose new hidden costs or procedural burdens.
They would be attentive to implementation details, timelines, and whether the FAA has capacity to produce clear guidance for clinicians and applicants.
A mainstream conservative would likely have mixed views: some will welcome transparency for applicants and clinicians, while others will be wary of another federal mandate that requires FAA to produce and maintain detailed lists and materials.
They may be concerned about expanding bureaucratic obligations, potential costs, and whether publication could expose the FAA to increased liability or politicization of medical determinations.
If framed strictly as publication of already-existing determinations and kept narrow in scope, many conservatives might view it as a tolerable or modest administrative change; if it creates new regulatory processes or costs, they would be more skeptical.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, this is a low-controversy, administratively focused bill that improves transparency and involves stakeholder input. It has limited fiscal impact and fits within existing FAA responsibilities, characteristics that historically increase chances of enactment. Passage still depends on procedural scheduling, committee priorities, and whether opponents raise specific technical or resource concerns during markup or amendment.
The bill has not accumulated any surfaced votes yet.
Transparency and worker safety vs. concerns about adding federal bureaucracy and cost.
On content alone, this is a low-controversy, administratively focused bill that improves transparency and involves stakeholder input. It ha…
Relative to its intended legislative type, this bill clearly defines a limited administrative task (publish and maintain a medication list for FAA medical certification), prescribes required content and stakeholder cons…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.